These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10997967)

  • 1. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
    Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
    Br J Haematol; 2000 Sep; 110(3):577-83. PubMed ID: 10997967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
    Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
    Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Randi ML; Fabris F; Girolami A
    Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Finazzi G; Barbui T
    Pathol Biol (Paris); 2001 Mar; 49(2):167-9. PubMed ID: 11317964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
    Candoni A; Tiribelli M; Fanin R
    Leuk Lymphoma; 2004 Apr; 45(4):821-4. PubMed ID: 15160964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Randi ML; Fabris F; Girolami A
    Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of essential thrombocythemia--personal experience].
    Bieniaszewska M; Balon J; Brozek I; Limon J; Hellmann A
    Pol Arch Med Wewn; 2000; 103(3-4):179-85. PubMed ID: 11236245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
    Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
    van den Anker-Lugtenburg PJ; Sizoo W
    Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
    Podoltsev NA; Zhu M; Zeidan AM; Wang R; Wang X; Davidoff AJ; Huntington SF; Giri S; Gore SD; Ma X
    J Natl Compr Canc Netw; 2019 Mar; 17(3):211-219. PubMed ID: 30865915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
    Passamonti F; Malabarba L; Orlandi E; Pascutto C; Brusamolino E; Astori C; Baratè C; Canevari A; Corso A; Bernasconi P; Cazzola M; Lazzarino M
    Br J Haematol; 2002 Mar; 116(4):855-61. PubMed ID: 11886392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
    Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
    Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
    Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
    Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.